Skip to main content

Table 5 Description and comparison of ORRs of clinical symptoms between the IFNα1b group and the control group after 7 days of treatment

From: Efficacy and safety of aerosol inhalation of recombinant human interferon α1b (IFNα1b) injection for noninfluenza viral pneumonia, a multicenter, randomized, double-blind, placebo-controlled trial

Control group8066.66 ± 36.29
IFNα1b group6777.93 ± 22.35
P 0.044